Glucagon like Peptide-1(GLP1) a Novel Therapeutic Strategy in Non-Alcoholic Fatty Liver Disease (NAFLD)

Non-alcoholic fatty liver disease (NAFLD) is a main cause of liver disease and its global prevalence is estimated to be 24%. At present no approved medicines are available for NAFLD treatment. Glucagon- like peptide-1 (GLP-1) is a significant regulator of energy balance and shows potential efficacy in the management of NAFLD. GLP-1 and GLP-1 receptor agonist (GLP-1RAs) are attractive options for the treatment of type 2 diabetes (T2D), since they efficiently reduce weight, HbA1C and blood glucose without having a risk of hypoglycaemia. Because of normalization of insulin resistance (IR), oxidative stress, lipid accumulation, lipotoxicity, and liver cell apoptosis, this incretin hormone is proposed for the management of NAFLD and non-alcoholic steatohepatitis (NASH). Hence, the aim of this review was to discuss the useful effects of GLP-1, GLP-1RAs, and dipeptidyl peptidase-4 (DPP-4) on NAFLD. In this paper we provided a new finding which highlighted the role of GLP-1 and GLP-1RAs in the treatment of NAFLD.